thyroid

multikinase inhibitor

Thesis

[KNOWN] Test as a conservative systemic option for progressive radioactive-iodine-refractory differentiated thyroid cancer. [INFERRED] The next increment should focus on biomarkers of response and combinations that preserve tolerability.

Mechanism

[KNOWN] Lenvatinib inhibits VEGFR, FGFR, PDGFR, RET, and KIT signaling, pathways implicated in angiogenesis and thyroid tumor growth. [INFERRED] Activity may be enriched in tumors dependent on angiogenic signaling.

Kill experiment

In a prospective cohort of molecularly characterized radioactive-iodine-refractory differentiated thyroid cancers, failure to reproduce objective responses or disease-control benefit at clinically relevant exposure would falsify the proposed biomarker-enriched increment.

Why it died

The query is undifferentiated thyroid disease, not progressive radioactive-iodine-refractory differentiated thyroid cancer. The pack supplies no thyroid-cancer subtype, mutation, target evidence, or causal path from VEGFR/FGFR/RET/KIT inhibition to a thyroid symptom. The thesis is also an established treatment claim, not an UNREVIEWED hypothesis; the CML calibration exception does not apply.

multikinase inhibitor

Thesis

[KNOWN] Test as an established systemic option for progressive radioactive-iodine-refractory differentiated thyroid cancer. [INFERRED] A useful increment is comparative selection against lenvatinib using molecular and toxicity profiles.

Mechanism

[KNOWN] Sorafenib inhibits RAF kinases and several receptor tyrosine kinases, including VEGFR and RET. [INFERRED] This may suppress both tumor-cell signaling and tumor angiogenesis.

Kill experiment

A head-to-head, adequately powered comparison against lenvatinib showing no clinically meaningful biomarker-defined efficacy or tolerability subgroup would falsify the proposed selection increment.

Why it died

This is an established systemic option for a particular advanced thyroid-cancer population, not an unreviewed hypothesis for the unspecified thyroid query. No mutation-to-signaling-to-symptom chain is provided, and the pack contains no thyroid cancer target or trial evidence. RAF/VEGFR/RET inhibition cannot be assumed to address autoimmune thyroiditis, hypothyroidism, or other meanings of thyroid disease.

BRAF inhibitor plus MEK inhibitor

Thesis

[KNOWN] Test in BRAF V600E-positive advanced thyroid cancers, particularly when MAPK-pathway dependence is documented. [INFERRED] The key increment is determining whether pathway inhibition can restore radioactive-iodine uptake in selected tumors.

Mechanism

[KNOWN] Dabrafenib inhibits mutant BRAF, while trametinib inhibits MEK1/2 downstream in the MAPK pathway. [INFERRED] MAPK suppression may increase thyroid differentiation in some BRAF-driven tumors.

Kill experiment

In BRAF V600E-positive thyroid cancer models and a genotype-selected clinical cohort, failure to produce pathway suppression with objective tumor responses or a reproducible radioactive-iodine-uptake signal would falsify the proposed increment.

Why it died

The candidate is restricted to BRAF V600E-positive advanced thyroid cancer, but the query provides no cancer diagnosis or BRAF alteration. The claim that MAPK suppression may restore radioactive-iodine uptake is explicitly INFERRED and stops before demonstrating restored thyroid differentiation or improved patient outcomes. It is a known targeted regimen rather than an UNREVIEWED hypothesis.

selective RET kinase inhibitor

Thesis

[KNOWN] Test in advanced thyroid cancer with an activating RET fusion or mutation. [INFERRED] Molecular selection is essential because unselected thyroid cancer is unlikely to provide a meaningful efficacy signal.

Mechanism

[KNOWN] Selpercatinib selectively inhibits oncogenic RET signaling. [INFERRED] RET-dependent tumors should be more sensitive than RET-negative tumors.

Kill experiment

Testing RET-fusion- or RET-mutation-positive thyroid cancer against RET-negative controls at matched exposure, followed by a genotype-selected clinical study, would falsify the hypothesis if RET-positive tumors showed no selective target engagement or response.

Why it died

The mechanism only applies to RET-dependent thyroid cancer, while TOP TARGETS [KG] and KNOWN DRUGS [KG] both returned none and no RET alteration is supplied. The chain from RET alteration to thyroid symptoms is missing, and the candidate is a clinically established precision therapy rather than an UNREVIEWED hypothesis. It is not justified for unspecified thyroid disease.

selective TRK inhibitor

Thesis

[KNOWN] Test only in thyroid cancers harboring an actionable NTRK1, NTRK2, or NTRK3 fusion. [INFERRED] This is a long-shot at the population level but a rational precision-therapy candidate in fusion-positive disease.

Mechanism

[KNOWN] Larotrectinib inhibits TRK proteins encoded by NTRK genes. [INFERRED] Blocking a tumor-driving TRK fusion may produce responses independent of thyroid histology.

Kill experiment

A small fusion-confirmed thyroid cancer cohort with independent response assessment would falsify the thyroid-specific hypothesis if NTRK-fusion-positive tumors lacked objective responses despite confirmed fusion expression and adequate drug exposure.

Why it died

This is a tumor-agnostic treatment for rare NTRK fusion-positive cancers, not a mechanism for the unspecified thyroid query. No NTRK fusion, thyroid cancer subtype, or causal route from TRK signaling to the reported thyroid phenotype appears in the pack. The proposed activity is already a known therapeutic claim, not an UNREVIEWED hypothesis.

PD-1 immune-checkpoint inhibitor

Thesis

[KNOWN] Test in selected advanced thyroid cancers with immunogenic features or no satisfactory targeted option. [INFERRED] Enrichment by PD-L1 expression, tumor mutational burden, mismatch-repair deficiency, or microsatellite instability may improve signal, but these biomarkers require disease-specific validation.

Mechanism

[KNOWN] Pembrolizumab blocks PD-1 signaling and can restore antitumor T-cell activity. [INFERRED] Benefit should be greatest where adaptive immune suppression is a relevant resistance mechanism.

Kill experiment

A prospective biomarker-stratified thyroid cancer cohort could falsify the hypothesis if PD-L1, TMB, MSI, and mismatch-repair status failed to identify any subgroup with reproducible response or durable disease control.

Why it died

PD-1 blockade is a broad immunotherapy hypothesis, but the pack does not establish an immune-mediated thyroid disease phenotype, tumor immunogenicity, or a mutation-to-antigen-to-symptom chain. The proposed biomarkers are explicitly INFERRED and require disease-specific validation. It also does not identify whether the query means thyroid cancer, Hashimoto thyroiditis, or hypothyroidism; the listed thyroid papers concern selenium, vitamin D, and older-adult hypothyroidism, not evidence for this mechanism.

repurposed oral metabolic drug

Thesis

[SPECULATIVE] Evaluate as an adjunctive repurposing hypothesis in thyroid cancer, not as a substitute for standard treatment. [INFERRED] The falsifiable increment is whether metformin produces a reproducible pharmacodynamic or clinical signal in a biomarker-defined subgroup.

Mechanism

[KNOWN] Metformin alters cellular energy and AMPK-associated signaling in experimental systems. [SPECULATIVE] These effects may constrain thyroid cancer growth or enhance sensitivity to kinase inhibition, but clinical antitumor benefit is unestablished here.

Kill experiment

A randomized adjunctive thyroid cancer study or a short pharmacodynamic window study showing no target-relevant signal and no improvement in tumor response or progression would falsify the proposed repurposing hypothesis.

Why it died

Although labeled SPECULATIVE, it supplies no thyroid-specific mutation, target, causal link, or symptom-level mechanism. The only [KNOWN] support is that metformin alters energy and AMPK-associated signaling in experimental systems; the thyroid antitumor effect is explicitly SPECULATIVE and clinical benefit is unestablished. This is insufficient to survive the mutation-to-symptom mechanism round.

antithyroid thionamide; wrong-but-plausible decoy

Thesis

[KNOWN] Methimazole treats thyroid hormone synthesis in hyperthyroidism, not established thyroid malignancy. [INFERRED] It is a useful decoy because thyroid hormone biology can appear causally adjacent to thyroid cancer without demonstrating tumor control.

Mechanism

[KNOWN] Methimazole inhibits thyroid peroxidase-mediated hormone synthesis. [INFERRED] This mechanism does not establish direct cytotoxicity or meaningful control of thyroid cancer.

Why it died

[KNOWN] Methimazole exists, but the pack itself states that it treats thyroid hormone synthesis in hyperthyroidism, not thyroid malignancy. Its thyroid-peroxidase mechanism does not establish tumor targeting, cytotoxicity, or meaningful control of thyroid cancer. It fails Round Triage as a wrong-disease decoy.